Thinly traded nano cap Hemispherx Biopharma (HEB +22.1%) is up on a 7x surge in volume in reaction to its announcement of two clinical trials evaluating the combination of Ampligen (rintatolimod) and Merck’s (MRK +0.4%) Keytruda (pembrolizumab).
The first will assess Ampligen when given prior to Keytruda in six triple-negative breast cancer (TNBC) patients. The objective is to determine if Ampligen boosts the effectiveness of Keytruda compared to Keytruda alone. The study, to be conducted at the Roswell Park Comprehensive Cancer Center in Buffalo, NY, should start shortly.
The second will evaluate the combination in 40 ovarian cancer patients at the University of Pittsburgh, also to determine if the combination outperforms Keytruda as monotherapy. It will commence later this month.
Source:|About: Hemispherx Biopharma, Inc (HEB)|By: Douglas W. House, SA News Editor
